Pulished Date October, 2018
ID: 2152
Share on
Share on

The Cancer Biomarkers Market is predicted to reach USD 17.2 billion with a CAGR of 14.5% according to Market Data Forecast report.

Pulished: October, 2018
ID: 2152
Pages: 0

The Cancer Biomarkers Market report published by Market Data Forecast provides a detailed account of the Market Trends via Customized Research presented as Strategic Analyses, Company Profiles, Competitive Landscape, etc. According to the report the Cancer Biomarkers Market is estimated to be USD 10.35 billion and predicted to rise to USD 17.2 billion with a CAGR of 11.45%. The market is segmented by Disease (Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer and Other Cancers), by Services (Sample Preparation, Assay development and Biomarkers validation and testing), by Application (Risk Assessment, Development of molecular diagnostics, Disease diagnosis, Drug discovery and Development and Drug formulation), by Type (Protein Biomarkers, Genetic biomarkers and Other biomarkers), by Profiling Technologies (Omics technologies, Imaging technologies, Immunoassays, Cytogenetics, Bioinformatics and IVD multivariate index assays). Further the market is also geographically segmented into North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa.

The increasing incidence of cancer, growing demand for highly developed diagnostics tests, improved awareness and acceptance of diagnostics tests, progression in technologies and the need for early stage cancer diagnosis propels the growth of this market. However, vague reimbursement scenario in certain countries and lack of specificity and sensitivity threaten to obstruct the growth of the cancer diagnostics market.

Breast cancer & prostate cancer biomarker market were among the largest disease indications included in the study. Growing prevalence of breast cancer and prostate cancer, increasing population with poor diet, high alcohol consumption, high calories intake, and rising demand for cosmetic surgeries among women are few factors driving the cancer biomarker market growth.

North America accounted for the largest market share in terms of revenue owing to rising demand for technically improved healthcare infrastructure. Asia Pacific is expected to be the fastest growing regions of cancer biomarker market.

Some of the major players in this market are Abbott Laboratories, Agendia Bv, Biocurex Inc, Biomerieux S.A., Biomoda Inc, Astellas Pharma Us Inc, Correlogic Systems Inc, Beckman Coulter Inc, Becton, Dickinson And Company, Clarient Inc, Diadexus Inc, Ambrilia Biopharma, Affymetrix Inc and Aureon Laboratories Inc.

Browse through the full report at “http://www.marketdataforecast.com/market-reports/global-cancer-biomarkers-market-2239/” and checkout our recent reports in the Molecular Diagnostics category at “http://www.marketdataforecast.com/research-reports/healthcare/molecular-diagnostics-4/”. For more insights and up-to-date industry news don’t forget subscribing to our newsletters.

LICENCE TYPE

$ 1234 0

Clients
clients
clients
clients
clients
clients
clients

Research Areas